Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: February 17, 2025
Reporting Period: The filing serves as a current report incorporating a press release dated February 17, 2025. The document itself does not specify a financial reporting period (e.g., Q4 2024) but rather discloses a specific event or announcement.
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing consists primarily of administrative details and an incorporation by reference to a press release (Exhibit 99.1), the content of which is not included in the input text.
Material Changes
The filing text does not provide details on material changes versus prior periods. It indicates that the report is incorporated by reference into registration statements on Form F-3 and Form S-8, but the specific nature of the update or change is not described in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. The document is a procedural filing to disseminate a press release, the substance of which is absent from the provided input.
Investor Verification Checklist
- Verify the content of the press release dated February 17, 2025 (Exhibit 99.1), as the summary of the announcement is not present in the filing text.
- Review the referenced registration statements (Form F-3 File No. 333-276164 and Form S-8 File No. 333-282031) to understand the context of the incorporation by reference.
- Check subsequent filings for detailed financial metrics if this 6-K was intended to accompany a financial update.